Sanctuary Advisors LLC Sells 21,709 Shares of Genmab A/S (NASDAQ:GMAB)

Sanctuary Advisors LLC cut its stake in Genmab A/S (NASDAQ:GMAB) by 66.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,091 shares of the company’s stock after selling 21,709 shares during the quarter. Sanctuary Advisors LLC’s holdings in Genmab A/S were worth $220,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of GMAB. International Assets Investment Management LLC bought a new position in shares of Genmab A/S in the third quarter worth about $254,000. Assetmark Inc. boosted its position in Genmab A/S by 16.2% in the 3rd quarter. Assetmark Inc. now owns 82,629 shares of the company’s stock valued at $2,014,000 after buying an additional 11,519 shares during the period. Atria Investments Inc grew its stake in Genmab A/S by 42.4% in the 3rd quarter. Atria Investments Inc now owns 48,475 shares of the company’s stock worth $1,182,000 after acquiring an additional 14,424 shares in the last quarter. Oppenheimer Asset Management Inc. increased its position in shares of Genmab A/S by 6.5% during the third quarter. Oppenheimer Asset Management Inc. now owns 232,243 shares of the company’s stock worth $5,662,000 after acquiring an additional 14,165 shares during the period. Finally, Natixis Advisors LLC raised its stake in shares of Genmab A/S by 29.8% during the third quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock valued at $5,036,000 after acquiring an additional 47,437 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on GMAB. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research note on Thursday, January 23rd. BMO Capital Markets reissued an “outperform” rating and set a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target for the company in a research report on Thursday, February 13th. Leerink Partnrs upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. Finally, Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. Four investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $42.17.

Genmab A/S Trading Up 3.3 %

NASDAQ GMAB opened at $24.10 on Thursday. The stock has a market capitalization of $15.95 billion, a price-to-earnings ratio of 13.85, a PEG ratio of 2.65 and a beta of 0.96. The stock has a 50-day moving average of $21.16 and a 200 day moving average of $22.71. Genmab A/S has a twelve month low of $18.64 and a twelve month high of $31.88.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Equities analysts predict that Genmab A/S will post 1.45 EPS for the current fiscal year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.